Editorials
Prescribing statins in general practice: who decides?

GPs have been debating the pros and cons of statins for different patients since the 4S trial back in 1994 first showed that statins could reduce mortality from strokes and heart attacks in those with existing cardiovascular disease. The whole country seemed to be debating them in September 2016, with Rory Collins explaining on BBC Radio 4’s Today programme that the benefits were ‘100 times the harms’. Collins had led a new review of the statins trials which concluded that the evidence strongly supported the benefits of statins and showed very modest risks. The review argued that ‘exaggerated claims about side effects’, often based on observational data, may have contributed to lower than recommended levels of statin use in individuals at increased risk of cardiovascular disease. Primary care data show that statin prescriptions are lower than recommended for high-risk groups.

The arguments about the evidence have been well rehearsed, and it is hard to come to any other conclusion than that statin therapy has prevented a great many heart attacks and strokes in those with pre-existing cardiovascular disease. Important gaps remain, however, such as uncertainties over the long-term harms of statin therapy; the greater incidence of side effects such as muscle pain seen in clinical practice than reported in trials; the lack of trial data on the elderly (at least until the results of the STAREE study in the over-70s become available after 2020); and, importantly, the difficulty of comparing risk in trial populations with the output of risk calculators such as QRISK2, which is routinely used in UK general practice. It is also premature to dismiss large observational datasets that, despite the problem of residual confounding, can help fill some of the gaps left by trial evidence, such as the effects of statins over longer follow-up periods than the usual 3–5 years seen in trials, and generalisability from trial participants to the general population in all its diversity.

THE BENEFITS OF PRIMARY PREVENTION ARE UNCERTAIN

The benefits from primary prevention are less clear, with a reduction in cardiovascular disease (CVD) events, but no reduction in all-cause mortality once those with pre-existing CVD are excluded. The US Preventive Services Task Force’s (USPSTF) recent guidance on statin therapy recommended ‘initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors [dyslipidemia, diabetes, hypertension, or smoking] and a calculated 10-year CVD event risk of 10% or greater’. For people over 75 years, they concluded that the ‘current evidence is insufficient to assess the balance of benefits and harms’.

This is similar to the National Institute for Health and Care Excellence (NICE) recommendation that GPs offer ‘atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.’ Four out of five men over 50 years, and most women over 60 years, fall into this group in the UK.

This new guidance from the USPSTF is unlikely to make statin therapy any less contentious. In the UK, Rory Collins has complained about the BMJ to the UK’s Committee on Publication Ethics, while Fiona Godlee (editor of the BMJ) has called for independent third-party scrutiny of the statins trial data to resolve the ‘bitter and unproductive’ dispute.

…” even if new evidence fills all the evidence gaps at population level, there will always be huge uncertainties for the individual patient.”

EXPERTS’ CONFLICT OF INTEREST

The controversy is about science, but also about conflicts of interest and transparency, as the science about statins has been almost exclusively funded by an industry where a single drug (atorvastatin) made up to £13 billion per year, the marketing spend was vast, and industry funding for the clinical trials unit at Oxford has been reported as hundreds of millions of pounds. The Cholesterol Treatment Trialists’ Collaboration (CTTC) hold the trial data, and have repeatedly ignored multiple calls to make them available for independent scrutiny. The CTTC’s refusal to release the data makes for a slippery hold on the moral high ground of the statins debate, in view of the importance of the individual patient data to the health of the world’s population. To many GPs it seems inexplicable, particularly now that most statins are off patent. And GPs are rightly cautious about blindly following the advice of experts, having had their fingers burnt in the past. Examples are the withdrawal of the COX-2 inhibitor rofecoxib after it had been prescribed to 80 million people, and the glitazone rosiglitazone, both of which were initially recommended in NICE guidance before being withdrawn.

But even if the data are eventually released for independent scrutiny, which they surely will be, and even if new evidence fills all the evidence gaps at population level, there

“Real progress will have been made when the BBC Today programme discusses the proportion of people who have made an informed decision about taking statins, rather than how many are failing to comply with expert advice.”
“Perhaps the most unfortunate aspect of the acrimonious statin debate is that it has hijacked conversations about reducing cardiovascular risk ...”

will always be huge uncertainties for the individual patient. Evidence of effectiveness at population level can and does sit alongside overwhelming uncertainty at individual level. We need routine use of better patient decision aid in GP consultations.11

require more of the time that is already in aid is interactive and equally good, but both to treat (NNT) of 25 over 10 years, which is in 100 is equivalent to a number needed to prevent heart disease (CHD) or having a stroke, will not develop CHD or have a stroke, and 96 will receive no benefit (90 people be saved from developing coronary disease and stroke. 2014. https://www.nice.org.uk/CG181 [accessed 5 May 2017].

REFERENCES


FROM PATERNALISM TO INFORMED CHOICE

In this context, the call from the CTTC experts that their advice should be followed more closely, with less debate and without independent review of the data, seems paternalistic. It does not resonate with GPs and patients in today’s world, where transparency of evidence is the norm, and the role of doctors is often to help patients apply uncertain evidence to their particular context and make their own choices.12

Informed choice may result in some people choosing not to be prescribed statins, just as some people choose not to take their prescribed medication, eat unhealthy foods, exercise sub-optimally, or even smoke.

Perhaps the most unfortunate aspect of the acrimonious statin debate is that it has hijacked conversations about reducing cardiovascular risk. Increasing physical activity, stopping smoking, and eating more healthily all reduce individual cardiovascular risk, while putting the person back in charge, rather than medicalising health and increasing dependency on doctors and drugs. Real progress will have been made when the BBC Today programme discusses the proportion of people who have made an informed decision about taking statins, rather than how many are failing to comply with expert advice.

Nick Steel,
Professor in Public Health, Norwich Medical School, Population Health and Primary Care, University of East Anglia, Norwich.

Bob Fleetcroft,
Honorary Senior Fellow, Norwich Medical School, Population Health and Primary Care, University of East Anglia, Norwich.

Yasmeen Hassan,
General Practice Specialty Trainee, Norwich Medical School, Population Health and Primary Care, University of East Anglia, Norwich.

Provenance
Commissioned; externally peer reviewed.

DOI: https://doi.org/10.3399/bjgp17X690953